Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

67.08 -1.31 (-1.92%)
Streaming Delayed Price Updated: 12:25 PM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Liquidia Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
LIQUIDIA CORP (NASDAQ:LQDA) Fits the Affordable Growth Screen ↗
Via Chartmill
News headline image
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia (LQDA) Q2 2026 Earnings Call Transcript ↗
YUTREPIA sales hit $170.4 million with 5,000+ patients started on therapy. 
Via The Motley Fool
Topics Earnings
Liquidia Corp (NASDAQ:LQDA) Shows High Growth Momentum With a Breakout Setup ↗
Via Chartmill
LIQUIDIA CORP (NASDAQ:LQDA): A High Growth Stock with a Strong Technical Setup ↗
Via Chartmill
News headline image
Why Liquidia Stock Was Diving This Week ↗
It needed to post a blowout quarter instead of the good one it delivered. 
Via The Motley Fool
News headline image
Liquidia Q2 Earnings Call Highlights ↗
Liquidia (NASDAQ:LQDA) reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical... 
Via MarketBeat
Topics Earnings
News headline image
Liquidia Corporation Reports Second Quarter 2026 Financial Results
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Corporation to Report Second Quarter 2026 Financial Results on August 12, 2026
From Liquidia Technologies, Inc.
Via GlobeNewswire
Liquidia Corp (NASDAQ:LQDA): An Affordable Growth Stock With Explosive Revenue Momentum and Reasonable Forward Valuation ↗
Via Chartmill
Liquidia Corp. (NASDAQ:LQDA) Flashes Perfect 10/10 Technical Score on Minervini Trend Template and High Growth Momentum ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA): Affordable Growth Play With Explosive Revenue ↗
Via Chartmill
News headline image
Transcript: Liquidia Q1 2026 Earnings Conference Call ↗
Liquidia (NASDAQ:LQDA) released first-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call... 
Via Benzinga
Topics Earnings
News headline image
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
From Liquidia Technologies, Inc.
Via GlobeNewswire
Liquidia Corp (NASDAQ:LQDA) Smashes Q1 Estimates as YUTREPIA Adoption Accelerates ↗
Via Chartmill
Liquidia Corp (NASDAQ:LQDA): High Growth Momentum Setup Nears Breakout ↗
Via Chartmill
News headline image
What to Know About This Fund’s $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260% ↗
Liquidia develops therapies for rare cardiopulmonary diseases, leveraging proprietary drug delivery technologies in the U.S. market. 
Via The Motley Fool
News headline image
Liquidia (LQDA) Q1 2026 Earnings Transcript ↗
Liquidia (LQDA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Liquidia Q1 Earnings Call Highlights ↗
Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and... 
Via MarketBeat
Topics Earnings
News headline image
Liquidia Corporation Reports First Quarter 2026 Financial Results
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth ↗
This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S. market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Liquidia Corporation to Participate in Upcoming Investor Conferences
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million ↗
Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its core market. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Liquidia Corporation to Participate in Upcoming Investor Conferences
From Liquidia Technologies, Inc.
Via GlobeNewswire
News headline image
Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock? ↗
This biotech focused on pulmonary therapies reported a notable insider sale amid strong share price gains and rising revenue. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.